11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Methotrexate Injection USP

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Metotrexat – högdos

Metotrexat – högdos

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.

  2. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17(3):818-24.

  3. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  4. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92(10):3569-77.

  5. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468-76.

  6. Grželj J, Marovt M, Marko PB, Mlinarič-Raščan I, Gmeiner T, Šmid A. Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina (Kaunas). 2021;57(10):.

  7. Mitruk S, Avihingsanon A, and Punyawudho B. Polymorphisms of ABCC2, ABCC4, ABCC10 and SLC22A6 in Thai HIV - infected patients. Chulalongkorn Medical Journal. 2014;58(6):599-611.

  8. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113(1):103-14.

  9. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.

  10. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother. 2009;21(2):205-10.

  11. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10(5):810-7.

  12. Methotrexate Ebewe (metotrexat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-07-24, cited 2024-03-17]

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.
  2. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17(3):818-24.
  3. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  4. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92(10):3569-77.
  5. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468-76.
  6. Grželj J, Marovt M, Marko PB, Mlinarič-Raščan I, Gmeiner T, Šmid A. Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina (Kaunas). 2021;57(10):.
  7. Mitruk S, Avihingsanon A, and Punyawudho B. Polymorphisms of ABCC2, ABCC4, ABCC10 and SLC22A6 in Thai HIV - infected patients. Chulalongkorn Medical Journal. 2014;58(6):599-611.
  8. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113(1):103-14.
  9. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.
  10. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother. 2009;21(2):205-10.
  11. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10(5):810-7.
  12. Methotrexate Ebewe (metotrexat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-07-24, cited 2024-03-17]